The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology / Q000528:radiation effects / Q000637:transplantation*; D008113:Liver Neoplasms / Q000628:therapy; D008175:Lung Neoplasms / Q000628:therapy; D008214:Lymphocytes / Q000276:immunology / Q000502:physiology; D008222:Lymphokines / Q000276:immunology / Q000494:pharmacology*; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000276:immunology / Q000494:pharmacology*; D012513:Sarcoma, Experimental / Q000097:blood / Q000378:metabolism / Q000628:therapy
D007376:Interleukin-2; D008222:Lymphokines; D011994:Recombinant Proteins